ReviewJournal of cardiovascular translational research2017
Translational Challenges in Cardiovascular Tissue Engineering.
Review in Journal of cardiovascular translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Paediatric aortic valve replacement: a meta-analysis and microsimulation study.European heart journal · 2023Pooled it
- In vivo validation of multimodality pore-network modeling to identify angio-permissive scaffold porosity.Materials today. Bio · 2026Article
- Pediatric pulmonary valve replacements: Clinical challenges and emerging technologies.Bioengineering & translational medicine · 2023Review
- Designing Biocompatible Tissue Engineered Heart Valves In Situ: JACC Review Topic of the Week.Journal of the American College of Cardiology · 2023Review
- Biological Scaffolds for Congenital Heart Disease.Bioengineering (Basel, Switzerland) · 2023Review
- Tissue engineering: Relevance to neonatal congenital heart disease.Seminars in fetal & neonatal medicine · 2022Review
- Residual immune response towards decellularized homografts may be highly individual.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2021Article
- Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity.Nature reviews. Cardiology · 2021Review
- Human iPSCs and Genome Editing Technologies for Precision Cardiovascular Tissue Engineering.Frontiers in cell and developmental biology · 2021Review
- Glycine Enhances Satellite Cell Proliferation, Cell Transplantation, and Oligonucleotide Efficacy in Dystrophic Muscle.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Differential Leaflet Remodeling of Bone Marrow Cell Pre-Seeded Versus Nonseeded Bioresorbable Transcatheter Pulmonary Valve Replacements.JACC. Basic to translational science · 2020Article
- Tissue Engineered Materials in Cardiovascular Surgery: The Surgeon's Perspective.Frontiers in cardiovascular medicine · 2020Review
- After 50 Years of Heart Transplants: What Does the Next 50 Years Hold for Cardiovascular Medicine? A Perspective From the International Society for Applied Cardiovascular Biology.Frontiers in cardiovascular medicine · 2019Article
- Preclinical Assessment of Cardiac Valve Substitutes: Current Status and Considerations for Engineered Tissue Heart Valves.Frontiers in cardiovascular medicine · 2019Review
- Cardiovascular tissue bioprinting: Physical and chemical processes.Applied physics reviews · 2018Review
- Heart valve scaffold fabrication: Bioinspired control of macro-scale morphology, mechanics and micro-structure.Biomaterials · 2018Article
- Tissue Engineering-Bridging the Gap.Journal of cardiovascular translational research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valvular heart disease and congenital heart defects represent a major cause of death around the globe. Although current therapy strategies have rapidly evolved over the decades and are nowadays safe, effective, and applicable to many affected patients, the currently used artificial prostheses are still suboptimal. They do not promote regeneration, physiological remodeling, or growth (particularly important aspects for children) as their native counterparts. This results in the continuous degeneration and subsequent failure of these prostheses which is often associated with an increased morbidity and mortality as well as the need for multiple re-interventions. To overcome this problem, the concept of tissue engineering (TE) has been repeatedly suggested as a potential technology to enable native-like cardiovascular replacements with regenerative and growth capacities, suitable for young adults and children. However, despite promising data from pre-clinical and first clinical pilot trials, the translation and clinical relevance of such TE technologies is still very limited. The reasons that currently limit broad clinical adoption are multifaceted and comprise of scientific, clinical, logistical, technical, and regulatory challenges which need to be overcome. The aim of this review is to provide an overview about the translational problems and challenges in current TE approaches. It further suggests directions and potential solutions on how these issues may be efficiently addressed in the future to accelerate clinical translation. In addition, a particular focus is put on the current regulatory guidelines and the associated challenges for these promising TE technologies.
Indexed as
Identifiers
28281240What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.